STOCK TITAN

Significant International Tier 1 Press Coverage on Xebra in Wake of Mexican Supreme Court Decision

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Xebra Brands Ltd. (CSE: XBRA, OTC: XBRAF) announced significant media coverage following its December 2 injunction from the Mexican Supreme Court, granting it a first-mover advantage in the CBD and CBG market. Coverage includes interviews with Chairman Robert Giustra on outlets like CNN en ESPAÑOL and Reuters. Xebra anticipates this advantage could last 1 to 3 years, potentially disrupting the U.S. and Canadian markets. The Mexican cannabis consumer market is expected to be lucrative, with projected sales reaching USD $102 million by 2026.

Positive
  • Injunction from Mexican Supreme Court grants Xebra a first-mover advantage in the CBD and CBG industry.
  • Significant international media coverage enhances brand visibility.
  • Projected sales in the Mexican cannabis market expected to reach USD $102 million by 2026.
Negative
  • None.

VANCOUVER, BC, Dec. 20, 2021 /PRNewswire/ - Xebra Brands Ltd. ("Xebra") (CSE: XBRA) (OTC: XBRAF) (FSE: 9YC), a cannabis company, reports that it has received significant news coverage by Mexican and international Tier 1 media, since the December 2nd announcement that it has received an injunction from the Mexican Supreme Court, granting it an outright first-mover advantage in the Mexican CBD and CBG industry.

The international media coverage includes interviews with Xebra's Chairman Robert Giustra and CNN en ESPAÑOL, Reuters and the Wall Street Journal (unpublished). The CNN interview aired on December 18, 2021 in the United States, Latin America and the Caribbean. The Reuters interview was published on December 17, 2021, and was also published by Forbes, among other noteworthy media outlets. In Mexico, Xebra received widespread coverage by all major media, including the top newspapers in politics, economy and finance, as well as Mexico's largest television broadcaster.

The significance and value of Xebra's Mexican injunction is just beginning to be understood by the global cannabis industry. Xebra believes its first-mover-advantage in Mexico could last 1 to 3 years, and that it can potentially disrupt the U.S. and Canadian CBD and CBG market, as cultivation and product manufacturing moves south to take advantage of more favorable costing, ideal climate, and the USMCA free trade agreement. In addition, the Mexican cannabis consumer market is expected to be lucrative.

Dozens of published articles can be found online, however following are links to selective recent media coverage on Xebra:

INTERNATIONAL COVERAGE

MEXICAN MEDIA COVERAGE

Additional third-party coverage on Xebra will be provided when available.

ON BEHALF OF THE BOARD:

Rodrigo Gallardo
President

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/significant-international-tier-1-press-coverage-on-xebra-in-wake-of-mexican-supreme-court-decision-301448058.html

SOURCE Xebra Brands Ltd.

FAQ

What is the significance of Xebra Brands' injunction from the Mexican Supreme Court?

The injunction grants Xebra Brands a first-mover advantage in the CBD and CBG market in Mexico, allowing it to lead in a potentially lucrative industry.

How does Xebra Brands plan to impact the U.S. and Canadian CBD markets?

Xebra anticipates that its first-mover advantage in Mexico could disrupt the U.S. and Canadian CBD and CBG markets by offering cost-effective production.

What recent media coverage has Xebra Brands received?

Xebra has received coverage from major outlets including CNN en ESPAÑOL, Reuters, and Bloomberg, highlighting its legal advancements and market potential.

What are the future sales projections for the cannabis market in Mexico?

The Mexican cannabis consumer market is expected to be significant, with sales projected to reach USD $102 million by 2026.

When did Xebra Brands receive the injunction from the Mexican Supreme Court?

Xebra Brands received the injunction on December 2, 2021.

XEBRA BRANDS LTD

OTC:XBRAF

XBRAF Rankings

XBRAF Latest News

XBRAF Stock Data

2.78M
27.22%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Vancouver